Alexia Ventures

Alexia Ventures is a Sao Paulo-based AI-focused fund backing data-driven software founders aiming at regional enterprise markets, with healthcare software and clinical AI sitting comfortably inside its remit. The firm writes Seed and Series A checks in the $1M to $5M range and typically targets Brazilian and broader LatAm founders building B2B platforms where machine learning is structurally embedded rather than sprinkled on top. Healthcare-relevant areas include revenue cycle automation for hospital networks and operadoras, clinical documentation and coding tools, diagnostic imaging AI, payer analytics, and SaaS layers that sit on top of legacy hospital management systems. The right founder for Alexia is technical, opinionated about data pipelines and model evaluation, and can articulate why their wedge product becomes a system of record rather than a feature. Founders pursuing pure care delivery, brick-and-mortar clinic chains, biotech, or hardware-led MedTech should look elsewhere; the fund is software-first and rewards capital efficiency. Geographic advantage is real here. Alexia knows the Brazilian enterprise buyer well, understands LGPD and ANS dynamics, and can introduce founders to operadoras de saude, hospital groups, and insurance buyers that out-of-region funds rarely reach. The firm has visibility into the regional AI talent pool and is comfortable with founders who plan to hire dense ML teams in Sao Paulo, Belo Horizonte, or Recife rather than only in the US. Best entry path is a warm intro from a current LatAm portfolio founder or an investor that has co-invested with Alexia, ideally accompanied by two or three reference customers in Brazil that can validate willingness-to-pay. Cold inbound is read but unlikely to convert without a unique technical or commercial signal. In the pitch, lead with the data asset: what proprietary clinical, claims, or operational data you accumulate, why competitors cannot replicate it, and how it compounds with scale. Show real customer conversations rather than letters of intent, and have a defensible answer on hospital integration cycles, which in Brazil routinely consume nine to eighteen months. Be ready to discuss model evaluation rigor, hallucination control if you ship LLMs into clinical settings, and how you monitor drift in production. Caveats are mostly stage-related. A Seed-to-Series A AI fund cannot underwrite long FDA or ANVISA pathways, so device classification matters; if your product is a SaMD with multi-year clearance timelines, position the cash flow story carefully. Watch concentration risk too, because Alexia, like most LatAm funds at this stage, prefers founders who can show a path beyond Brazil into Mexico, Colombia, and Chile within twenty-four months of Series A. If your wedge is genuinely Brazil-only, be honest and price the round accordingly.